Celgene (BUE:CELG) Inventories, Raw Materials & Components: ARS12,862.98 Mil (As of Sep. 2019)


What is Celgene Inventories, Raw Materials & Components?

Celgene BUE:CELG 10 Inventories, Raw Materials & Components is ARS12,862.98 Mil as of Sep. 2019. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Celgene's inventories, raw materials & components for the quarter that ended in Sep. 2019 was ARS12,862.98 Mil.

Celgene's quarterly raw materials increased from Mar. 2019 (ARS9,186.15 Mil) to Jun. 2019 (ARS11,795.26 Mil) and increased from Jun. 2019 (ARS11,795.26 Mil) to Sep. 2019 (ARS12,862.98 Mil).

Celgene's annual raw materials increased from Dec. 2016 (ARS4,343.59 Mil) to Dec. 2017 (ARS5,518.46 Mil) and increased from Dec. 2017 (ARS5,518.46 Mil) to Dec. 2018 (ARS9,501.66 Mil).

Celgene Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Celgene's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene Inventories, Raw Materials & Components Chart

Celgene Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,710.20 2,605.43 4,343.59 5,518.46 9,501.66

Celgene Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,966.10 9,501.66 9,186.15 11,795.26 12,862.98

Celgene Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of ARS12,862.98 Mil mean?
Celgene (BUE:CELG) has a Inventories, Raw Materials & Components of ARS12,862.98 Mil as of Sep. 2019. Raw materials are the components a company uses for its main products. View historical data on Celgene and its competitors.
Is Celgene's Inventories, Raw Materials & Components too high?
Celgene's current Inventories, Raw Materials & Components is ARS12,862.98 Mil. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's Inventories, Raw Materials & Components compare to GILD and BIIB?
Celgene's Inventories, Raw Materials & Components of ARS12,862.98 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Celgene and its competitors. Celgene's current Inventories, Raw Materials & Components is ARS12,862.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current Inventories, Raw Materials & Components of ARS12,862.98 Mil. The current Inventories, Raw Materials & Components is ARS12,862.98 Mil. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Celgene (BUE:CELG), the current Inventories, Raw Materials & Components is ARS12,862.98 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celgene Business Description

Address 86 Morris Avenue, Summit, NJ, USA, 07901
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.